The information you are about to see is intended for U.S. healthcare professionals.
Thank you for your request!
INDICATIONS AND USAGE
Galafold® (migalastat) is indicated for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene (GLA) variant based on in vitro assay data.
This indication is approved under accelerated approval based on reduction in kidney interstitial capillary cell globotriaosylceramide (KIC GL-3) substrate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
Goes Where Your Patients Go
An oral option for adults with confirmed Fabry disease and an amenable galactosidase alpha gene (GLA) variant associated with either the classic* or non-classic phenotype.1,2
*
Defined as males with residual peripheral blood mononuclear cell alpha-galactosidase A (alpha-Gal A) <3% of normal and multiorgan system involvement.2
Start a Patient
Start a Patient
The Galafold Patient Referral Form serves both as a prescription for Galafold in some states and a referral to AMICUS ASSIST®.
Download the form